Self-reported memory complaints
Implications from a longitudinal cohort with autopsies
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 19, 2013
- Accepted in final form July 12, 2014
- First Published September 24, 2014.
Article Versions
- Previous version (September 24, 2014 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Richard J. Kryscio, PhD,
- Erin L. Abner, PhD,
- Gregory E. Cooper, MD, PhD,
- David W. Fardo, PhD,
- Gregory A. Jicha, MD, PhD,
- Peter T. Nelson, MD, PhD,
- Charles D. Smith, MD,
- Linda J. Van Eldik, PhD,
- Lijie Wan and
- Frederick A. Schmitt, PhD
- Richard J. Kryscio, PhD,
Scientific Advisory board, ALLTECH Inc.
NONE
NONE
Associate Editor, Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Alzheimer Disease Center Core grant: AG028383, 7/11 - 6/16 Associate Director; Core Leader: Biostatistics and Data Management National Institute on Aging grants R01 AG0386561-01A1, 07/11-06/16, P.I. P01AG05119, 4/08 - 3/13, co-investigator R01AG019241, 9/01 -2/13, co-P.I. R03AG032099, 6/10 - 5/12, co-investigator R21AG036875, 6/10 - 5/12, co-investigator National Center for Research Resources P20RR020145, 9/04 - 7/14, Leader Biostatistcs and Bioinformatics Core U54 RR031263, 7/11 - 6/16, Leader, Biostatistcs, Epidemiology, and Research Design National Institute on Drug Abuse P50DA005312, 9/06 - 6/12, co-investigator National Institute of Neurological Diseases & Stroke P01NS058484, 5/09 - 4/12, co-investigator National Institute of child health & Human Development R01HD064993, 9/09-8/14, co-investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Erin L. Abner, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Alltech Life Sciences
(1) NIA P30 AG028383, Co-investigator, 2006-present (2) NIA R01 AG019241, Co-investigator, 2006-present (3) NIA R01 AG038651, Co-investigator, 2011-present (4) NIH R01 NR014189, Co-investigator, 2013-present (5) NIH R01 HD064993, Co-investigator, 2013-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory E. Cooper, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Pfizer Speakers Bureau (2007-2009); Forest Pharmaceuticals Speakers Bureau (2007-2014)
NONE
NONE
Grant funding from Eli Lilly (2008-present), Myriad Pharmaceuticals (2007-2009)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Provided expert consultation regarding nursing home care of patients with dementia;
- David W. Fardo, PhD,
NONE
NONE
NONE
(1) Journal of Pediatric Genetics, Statistical Editor, 2010-present (2) Frontiers in Applied Genetic Epidemiology, Review Editor, 2011-present (3) Journal of Biometrics and Biostatistics, Editorial Board, 2012-present
NONE
NONE
NONE
(1) Brigham Young University (2) Commonwealth Center for Governance Studies, Inc.
NONE
NONE
NONE
NONE
(1) NIH/NIA, K25 AG043546, PI, 2013-present (2) NIH/NIA, P30 AG028383, Biostatistics and Data Management, 2012-2013 (3) NIH/NIA, R01 AG038651, Co-I, 2012-2013 (4) NIH/NIDCR, R03 DE021438, Co-I, 2012-2013 (5) NIH/NIGMS, P20 GM103436, Co-I, 2012-2013 (6) NIH/NIGMS, P20 GM103538, Co-I, 2012-2013 (7) NIH/NIA, R01 AG019241, Co-I, 2012-2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory A. Jicha, MD, PhD,
NONE
NONE
NONE
1)Journal of International Clinical and Experimental Medicine, Associate Editor, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Pfizer Jannsen Lilly Alltech Baxter Esai
P30AG028383, R01AG019241, R01HD064993, R01NR014189, R01AG038651, UL1TR000117, U01AG010483
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter T. Nelson, MD, PhD,
Mayo Jacksonville Udall Ctr
NONE
NONE
Acta Neuropathologica JNEN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
5P30AG028383-08 (Van Eldik, PI) 7/01/2006 -06/30/2016 2.4 calendar NIH/NIA $854,767 Alzheimer�s Disease Center The major goal of this project is to build on the existing broad-based AD program to gain an understanding of pathogenic mechanisms in AD with the eventual goal of prevention and treatment of the disease. No overlap. 5R01AG0386561-02 (Kryscio & Schmitt, PIs) 9/01/11- 8/31/16 1.20 calendar NIH/NIA $502,948 Role of impaired cognitive states & risk factors in conversion to mixed dementias Combine data from six centers having longitudinal cohorts assessed for cognitive status annually and followed to dementia with autopsy upon death. Use of innovative Markov model to risk factors to the flow of elderly subjects through impaired cognitive states and correlate with neuropathological assessment of the brain upon autopsy. No overlap. 5R01NR014189-02 (G. Jicha, D. Moser) 09/01/2012 � 08/31/2017 0.60 calendar NIH/NINR $270,423 Early Detection and Prevention of Mild Cognitive Impairment due to cerebrovascular A multidisciplinary approach to studying MCI related to cerebral vascular disease. No overlap. R56NS061933-05A1 (Nelson) 09/28/2012- 08/31/2014 1.20 calendar NIH/NIA $250,000MIR-15/107 micrornas are important genetic regulators in Alzheimer disease This is a no-cost extension with a prior R01 that highlighted the impact of miR-15/107 miRNAs in AD according to biosamples from a brain bank, and from tissue culture experimental systems. No overlap. 1R01AG042419-01A1 (G. Jicha, P. Nelson) 07/15/2013 � 06/30/2016 1.20 calendar NIH/NIA $352,667 Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease Basically a small-scale clinical trial for gemfibrozil, studying mechanisms of action and biodistribution. No overlap. 1R21NS085830-01 (Nelson) 09/01/2013 � 08/31/2015 0.48 calendar NINDS /NIH $150,000 Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy Study of a miRNA in connection with dementia with Lewy bodies. No overlap.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charles D. Smith, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Neuronetrix, Inc., (2) AmGen, Inc.
(1) NIH/NIA P50 AG 5119 Satellite PI, (2) NIH/NIA T32 000242 Faculty, (3) NIH/NIA U01 AG024904 Site PI, (4) NIH/NIMH R01MH078228 Co-investigator, (5) NIH/NCRR (Shared Instrumentation) 1S10RR024553 PI, (6) NIH/NIMH R01MH063817-04 Co-investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Linda J. Van Eldik, PhD,
NONE
NONE
NONE
(1) Journal of Neuroinflammation, editorial board member, 2003-present. (2) Journal of Neuroimmune Pharmacology, editorial board member, 2007-present. (3) American Journal of Neurodegenerative Disease, editorial board member, 2012-present.
(1) Synthetic peptides and use in preparing calmodulin antisera. (2) Several patents for composition and use of pyridazine compounds.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH R01 NS064247, Principal investigator, 2010-2014 (2) NIH P30 AG028383, Principal investigator, 2010-2016 (3) Kentucky Spinal Cord & Brain Injury Research Trust 12-20A research grant, Principal investigator, 2013-2016
NONE
(1) Thome Memorial Foundation research award, Principal investigator, 2010-2014
NONE
NONE
NONE
NONE
NONE
NONE
- Lijie Wan and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frederick A. Schmitt, PhD
Scientific Advisory board, ALLTECH Inc.
NONE
NONE
Associate Editor, Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Alzheimer Disease Center Core grant: AG028383, 7/11 - 6/16 Associate Director; Core Leader: Biostatistics and Data Management National Institute on Aging grants R01 AG0386561-01A1, 07/11-06/16, P.I. P01AG05119, 4/08 - 3/13, co-investigator R01AG019241, 9/01 -2/13, co-P.I. R03AG032099, 6/10 - 5/12, co-investigator R21AG036875, 6/10 - 5/12, co-investigator National Center for Research Resources P20RR020145, 9/04 - 7/14, Leader Biostatistcs and Bioinformatics Core U54 RR031263, 7/11 - 6/16, Leader, Biostatistcs, Epidemiology, and Research Design National Institute on Drug Abuse P50DA005312, 9/06 - 6/12, co-investigator National Institute of Neurological Diseases & Stroke P01NS058484, 5/09 - 4/12, co-investigator National Institute of child health & Human Development R01HD064993, 9/09-8/14, co-investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Sanders-Brown Center on Aging (R.J.K., E.L.A., G.E.C., G.A.J., P.T.N., C.D.S., L.J.V.E., L.W., F.A.S.), Alzheimer's Disease Center (R.J.K., E.L.A., G.E.C., D.W.F., G.A.J., P.T.N., C.D.S., L.J.V.E., F.A.S.), Departments of Biostatistics (R.J.K., D.W.F.), Statistics (R.J.K., L.W.), Epidemiology (E.L.A.), and Pathology (P.T.N.), Department of Anatomy and Neurobiology, College of Medicine (L.J.V.E.), and Department of Neurology, College of Medicine (G.A.J., C.D.S., F.A.S.), University of Kentucky, Lexington; and Baptist Neurology Center (G.E.C.), Lexington, KY.
- Correspondence to Dr. Kryscio: kryscio{at}email.uky.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Subjective Memory Complaint and Clinical Impact
- Frederick A. Schmitt, Professor, University of Kentuckyfascom@uky.edu
- Erin Abner, Lexington,KY; Richard Kryscio, Lexington, KY
Submitted March 13, 2015 - Response to "Self-reported memory complaints: Implications from a longitudinal cohort with autopsies"
- Amy Jenkins, PhD Researcher, Swansea University643775@swansea.ac.uk
- Anthony Bayer, Cardiff, UK; Jeremy Tree, Swansea, UK; Andrea Tales, Swansea, UK
Submitted November 18, 2014
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.